The Øie–Tozer model of drug distribution and its suitability for drugs with different pharmacokinetic behavior

Abstract

Introduction: Drug distribution is a major pharmacokinetic process that affects the time course of drug concentrations in tissues, biological fluids and the resulting pharmacological activities. Drug distribution may follow different pathways and patterns, and is governed by the drug's physicochemical properties and the body's physiology. The classical Øie–Tozer model is frequently used for predicting volume of drug distribution and for pharmacokinetic calculations.

Areas covered: In this review, the suitability of the Øie–Tozer model for drugs that exhibit different distribution patterns is critically analyzed and illustrated. The method used is a pharmacokinetic modeling and simulation approach. It is demonstrated that the major limitation of the Øie–Tozer model stems from its focus on the total drug concentrations and not on the active (unbound) concentrations. Moreover, the Øie–Tozer model may be inappropriate for drugs with nonlinear or complex pharmacokinetic behavior, such as biopharmaceuticals, drug conjugates or for drugs incorporated into drug delivery systems. Distribution mechanisms and alternative distribution models for these drugs are discussed.

Expert opinion: The Øie–Tozer model can serve for predicting unbound volume of drug distribution for 'classical' small molecular mass drugs with linear pharmacokinetics. However, more detailed mechanism-based distribution models should be used in preclinical and clinical settings for drugs that exhibit more complex pharmacokinetic behavior.

Keywords:

• displacement of drug from plasma proteins
• pharmacokinetic modeling
• plasma protein binding
• volume of distribution

Notes

This box summarizes key points contained in the article.